Compare Stocks → This AI Trade Machine Made 1,729%* (With 89% Wins) (From Prosper Trading Academy) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NYSE:ALRNASDAQ:CADLNASDAQ:GYRENASDAQ:MODD Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALRAlere$1.32$0.00$34.41▼$51.00$43.05M0.8540,839 shsN/ACADLCandel Therapeutics$6.39-0.6%$3.11$0.66▼$11.40$187.53M0.9216.47 million shs391,978 shsGYREGyre Therapeutics$17.11+4.8%$17.65$3.00▼$30.40$1.46B2.1167,940 shs190,253 shsMODDModular Medical$1.58+5.3%$1.77$0.84▼$2.22$34.60M0.43108,833 shs10,057 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALRAlere0.00%0.00%0.00%0.00%0.00%CADLCandel Therapeutics0.00%+23.60%+304.43%+430.29%+376.87%GYREGyre Therapeutics0.00%+10.32%-2.12%+14.60%+1,710,999,900.00%MODDModular Medical0.00%-3.07%-14.59%-17.28%-21.00%This AI Trade Machine Made 1,729%* (With 89% Wins) (Ad)This A.I. trading software called out an options trade the other day with a nearly perfect historical win rate… And a cumulative gain of 1729%. How does it all work?Click Here To Get Your Free CopyMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALRAlereN/AN/AN/AN/AN/AN/AN/AN/ACADLCandel Therapeutics1.1892 of 5 stars3.52.00.00.01.11.70.0GYREGyre Therapeutics0.1999 of 5 stars0.03.00.00.02.50.00.6MODDModular Medical3.6232 of 5 stars3.55.00.00.03.13.30.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALRAlereN/AN/AN/AN/ACADLCandel Therapeutics3.00Buy$11.0072.14% UpsideGYREGyre TherapeuticsN/AN/AN/AN/AMODDModular Medical3.00Buy$4.25168.99% UpsideCurrent Analyst RatingsLatest ALR, MODD, CADL, and GYRE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/21/2024MODDModular MedicalBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSpeculative Buy ➝ Speculative Buy$5.00(Data available from 4/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALRAlere$934.59M0.05N/AN/A$5.72 per share0.23CADLCandel Therapeutics$120K1,562.73N/AN/A$0.44 per share14.52GYREGyre Therapeutics$113.45M12.88$0.26 per share65.65$0.18 per share95.06MODDModular MedicalN/AN/AN/AN/A$0.46 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALRAlere-$29.92M-$1.20N/AN/AN/A-5.34%-20.78%-9.02%N/ACADLCandel Therapeutics-$37.94M-$1.30N/A∞N/AN/A-142.91%-69.87%5/9/2024 (Estimated)GYREGyre Therapeutics-$92.93M-$20.69N/AN/AN/AN/AN/A-228.91%5/20/2024 (Estimated)MODDModular Medical-$13.88M-$0.97N/AN/AN/AN/A-235.93%-180.37%6/24/2024 (Estimated)Latest ALR, MODD, CADL, and GYRE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023CADLCandel Therapeutics-$0.16-$0.38-$0.22-$0.38N/AN/A2/13/2024Q3 2024MODDModular Medical-$0.17-$0.23-$0.06-$0.23N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALRAlereN/AN/AN/AN/AN/ACADLCandel TherapeuticsN/AN/AN/AN/AN/AGYREGyre TherapeuticsN/AN/AN/AN/AN/AMODDModular MedicalN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALRAlere0.451.581.58CADLCandel Therapeutics0.972.592.59GYREGyre TherapeuticsN/A2.852.64MODDModular MedicalN/A1.631.63OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALRAlere24.08%CADLCandel Therapeutics13.93%GYREGyre Therapeutics23.99%MODDModular Medical27.47%Insider OwnershipCompanyInsider OwnershipALRAlere8.40%CADLCandel Therapeutics44.60%GYREGyre Therapeutics2.92%MODDModular Medical32.34%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableALRAlere10,40032.61 million29.87 millionOptionableCADLCandel Therapeutics4229.35 million16.26 millionOptionableGYREGyre Therapeutics59385.42 million82.93 millionNo DataMODDModular Medical3721.90 million14.82 millionNot OptionableALR, MODD, CADL, and GYRE HeadlinesSourceHeadlineCritical Contrast: Modular Medical (NASDAQ:MODD) & OrthoPediatrics (NASDAQ:KIDS)americanbankingnews.com - April 28 at 2:00 AMModular Medical (NASDAQ:MODD) Trading Down 4.1%americanbankingnews.com - April 20 at 2:30 AMSmall Business Week: Modular Solutions, Ltd educates clients about a superior way to buildbizjournals.com - April 19 at 1:47 PM7 Best Video Conferencing Software of April 2024newsweek.com - April 7 at 6:33 PMBest Mods For Content Warningmsn.com - April 7 at 6:33 PMBEML Share Pricebusiness-standard.com - March 29 at 5:09 AMModular Medical, Inc.: Modular Medical Announces Steve Gemmell as New Vice President of Engineeringfinanznachrichten.de - March 26 at 10:52 AMModular Medical Announces Steve Gemmell as New Vice President of Engineeringfinance.yahoo.com - March 26 at 10:52 AMWeekend News Roundup March 16, 2024msn.com - March 16 at 12:50 PMRegistration Is Now Open for Tribe Public's Webinar Event "Revolutionizing Diabetes Care" Featuring Modular Medical CEO on Wednesday, March 6, 2024accesswire.com - March 4 at 8:00 AMModular Medical Stock (NASDAQ:MODD) Earnings Dates and Earning Callsbenzinga.com - February 25 at 3:31 PMModular Medical, Inc.: Modular Medical Announces Closing of $10 Million Public Offeringfinanznachrichten.de - February 21 at 9:03 PMModular Medical Announces Closing of $10 Million Public Offeringfinance.yahoo.com - February 21 at 9:03 PMModular Medical Announces Closing of $10 Million Public Offeringaccesswire.com - February 21 at 4:05 PMModular Medical, Inc.: Modular Medical Announces Proposed Public Offeringfinanznachrichten.de - February 16 at 2:38 AMModular Medical announces proposed underwritten public offeringseekingalpha.com - February 16 at 2:38 AMModular Medical Announces Pricing of $10 Million Public Offeringfinance.yahoo.com - February 15 at 8:54 PMModular Medical Announces Proposed Public Offeringfinance.yahoo.com - February 15 at 8:54 PMModular Medical Announces Pricing of $10 Million Public Offeringaccesswire.com - February 15 at 8:45 PMModular Medical Announces Proposed Public Offeringaccesswire.com - February 15 at 4:15 PMreliance naval engineering ltd agm share price Management discussionsindiainfoline.com - February 5 at 6:43 PMStarfield Player Builds Incredible Charizard Shipmsn.com - February 3 at 12:52 PMModular Medical, Inc. (MODD) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?msn.com - February 2 at 3:47 PMModular Medical picks up new insulin pump patent for mobile device connectivitydrugdeliverybusiness.com - February 2 at 10:47 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Stocks Leading the U.S. Agriculture ComebackApril 26, 2024 10:10 AMView 3 Stocks Leading the U.S. Agriculture ComebackStock market today: Alphabet and Microsoft help Wall Street clinch its best week in nearly 6 monthsApril 26, 2024 3:21 AMView Stock market today: Alphabet and Microsoft help Wall Street clinch its best week in nearly 6 monthsHow to Use Put Debit Spreads to Profit From Falling Stocks April 26, 2024 9:30 AMView How to Use Put Debit Spreads to Profit From Falling Stocks Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower PricesApril 25, 2024 10:36 AMView Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower PricesUnusually High Volume Points to Upside in These StocksApril 5, 2024 7:45 AMView Unusually High Volume Points to Upside in These StocksAll Headlines Company DescriptionsAlereNYSE:ALRAlere Inc. is a provider of health information through diagnostic tests. The Company's segments include professional diagnostics, consumer diagnostics, and corporate and other. The professional diagnostics segment includes an array of diagnostic test products and other in vitro diagnostic tests marketed to medical professionals and laboratories for detection of diseases and conditions within its areas of focus. The consumer diagnostics segment consists primarily of manufacturing operations related to its role as the exclusive manufacturer of products for SPD Swiss Precision Diagnostics (SPD), its joint venture with The Procter & Gamble Company (P&G). The Company's professional diagnostic solutions allow patients and their healthcare providers to work together to manage patients' conditions over the continuum of care, from the hospital to home. The Company offers lines of drugs-of-abuse tests, reagent systems and laboratory testing options.Candel TherapeuticsNASDAQ:CADLCandel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is based in Needham, Massachusetts.Gyre TherapeuticsNASDAQ:GYREGyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.Modular MedicalNASDAQ:MODDModular Medical, Inc. operates as a development stage medical device company. It focuses on the design, development, and commercialization of insulin pumps. It offers MODD1, a two-part patch pump for diabetes. The company was founded in 1998 and is headquartered in San Diego, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.